Transgenerational epigenetic imprinting of the male germline by endocrine disruptor exposure during gonadal sex determination.
Embryonic exposure to the endocrine disruptor vinclozolin at the time of gonadal sex determination was previously found to promote transgenerational disease states. The actions of vinclozolin appear to be due to epigenetic alterations in the male germline that are transmitted to subsequent generations. Analysis of the transgenerational epigenetic effects on the male germline (i.e. sperm) identified 25 candidate DNA sequences with altered methylation patterns in the vinclozolin generation sperm. These sequences were identified and mapped to specific genes and noncoding DNA regions. Bisulfite sequencing was used to confirm the altered methylation pattern of 15 of the candidate DNA sequences. Alterations in the epigenetic pattern (i.e. methylation) of these genes/DNA sequences were found in the F2 and F3 generation germline. Therefore, the reprogramming of the male germline involves the induction of new imprinted-like genes/DNA sequences that acquire an apparent permanent DNA methylation pattern that is passed at least through the paternal allele. The expression pattern of several of the genes during embryonic development were found to be altered in the vinclozolin F1 and F2 generation testis. A number of the imprinted-like genes/DNA sequences identified are associated with epigenetic linked diseases. In summary, an endocrine disruptor exposure during embryonic gonadal sex determination was found to promote an alteration in the epigenetic (i.e. induction of imprinted-like genes/DNA sequences) programming of the male germline, and this is associated with the development of transgenerational disease states.
Chang
Hung-Shu
HS
Center for Reproductive Biology, School of Molecular Biosciences, Washington State University, Pullman, Washington 99164-4231, USA.
Anway
Matthew D
MD
Rekow
Stephen S
SS
Skinner
Michael K
MK
D000818:Animals; D001483:Base Sequence; D002874:Chromosome Mapping; D019175:DNA Methylation; D052244:Endocrine Disruptors / Q000009:adverse effects*; D044127:Epigenesis, Genetic / Q000187:drug effects / Q000235:genetics; D005260:Female; D030342:Genetic Diseases, Inborn / Q000139:chemically induced / Q000235:genetics; D018392:Genomic Imprinting / Q000187:drug effects / Q000235:genetics; D005854:Germ Cells / Q000187:drug effects; D008297:Male; D018811:Maternal Exposure / Q000009:adverse effects*; D008969:Molecular Sequence Data; D010080:Oxazoles / Q000009:adverse effects*; D051381:Rats; D011916:Rats, Inbred F344; D017207:Rats, Sprague-Dawley; D019849:Sex Determination Processes
D052244:Endocrine Disruptors; D010080:Oxazoles; C025643:vinclozolin